Hybrisan has been acquired by Eumar

Cardiff – CFI is pleased to announce that it acted as exclusive financial advisor with Hybrisan on its sale to Eumar Technology.

Hybrisan, founded in 2013, has built a strong reputation in chronic wound care. Its lead product, WoundSan®, is a clinically evidenced wound cleansing technology currently progressing through EU MDR approval and expected to reach the market later this year. Hybrisan will continue to operate from its headquarters in Port Talbot, with increased investment from its new owners in its South Wales innovation hub.

Founded in 1985 and headquartered in Hereford, Eumar Technology is a specialist medical device manufacturer serving the global wound care market.

This move establishes a clearly defined and complementary structure, combining Eumar Technology’s ISO 13485-certified manufacturing facilities and superabsorbent materials expertise with Hybrisan’s product development expertise in electrospinning and antimicrobials.

Chris Mortimer, Chief Technology Officer (formerly CEO, Hybrisan): “Combining Hybrisan’s development expertise with Eumar’s manufacturing capability, infrastructure and commercial reach will allow us to accelerate innovative wound care solutions to market. The continuation of operations in Port Talbot ensures the specialist skills we have built in South Wales remain central to the group’s future.”

Euan Davidson, Chairman, Eumar Technology: “This acquisition is central to our long-term strategy to build a leading UK medical device business. We are committed to investing in skilled employment and manufacturing excellence across both Herefordshire and South Wales, with the goal of creating a CDMO recognised internationally for taking innovative products from concept to commercial manufacture entirely within the United Kingdom.”

This transaction closed on 5 June 2026.